EUVIMEDEUVIMED entdecken
Crossref

Discovery of a Quinazoline-Based Nav1.7 Inhibitor with MicroED-Confirmed Absolute Configuration and Oral Efficacy in Rodent Models of Neuropathic Pain

Jae Ho Shim iD, Pooreum Lim, Sangwoo Woo, Jihye Han, Hyeon Soo Kim

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.6c02422 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Jae Ho Shim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, Korea University College of Medicine, 73 Inchon-ro Seongbuk-gu, Seoul02841, Republic of Korea. Hauptthemen laut MEDLINE: Quinazolines, NAV1.7 Voltage-Gated Sodium Channel, Neuralgia, Analgesics. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Korea University, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selective Nav1.7 inhibition is a genetically validated, non-opioid strategy for chronic neuropathic pain. Herein, we report the structure-guided discovery of a quinazoline-based Nav1.7 inhibitor series. From a focused-library hit A1 (IC50 = 15.2 μM), systematic SAR across 19 analogs yielded the chiral lead (R)-(+)-A11 (IC50 = 0.98 μM; 53.9-fold selectivity over Nav1.5), with absolute configuration confirmed by MicroED (Flack x = 0.03(12)). (R)-(+)-A11 displayed favorable oral pharmacokinetics (F = 28.2%, free Cmax = 1.06 μM) and dose-dependent analgesia in mouse formalin (ED50 = 18.5 mg/kg) and rat CCI (83% MPE; ED50 = 17.1 mg/kg) models. Off-target profiling of A11 (racemate) against 44 targets showed <10% inhibition at 10 μM, and DRG CGRP target engagement by (R)-(+)-A11 (IC50 = 0.42 μM), with Nav1.7-KO neuron controls supporting Nav1.7 as the primary mechanism. These results establish (R)-(+)-A11 as a promising quinazoline lead for non-opioid neuropathic pain therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinazolinesNAV1.7 Voltage-Gated Sodium ChannelNeuralgiaAnalgesicsDrug DiscoveryVoltage-Gated Sodium Channel BlockersAnimalsMiceStructure-Activity RelationshipRatsAdministration, OralHumansMaleRats, Sprague-DawleyDisease Models, AnimalStereoisomerism

Stichwörter der Autor:innen

MicroEDNav1.7enantioselectivityneuropathic painoral analgesicquinazolinesodium channel inhibitorstructure−activity relationship

Substanzen

QuinazolinesNAV1.7 Voltage-Gated Sodium ChannelAnalgesicsVoltage-Gated Sodium Channel Blockers

Autor:innen und Institutionen

  • Department of Anatomy, Korea University College of Medicine, 73 Inchon-ro Seongbuk-gu, Seoul02841, Republic of Korea.

ORCID-Profile: Jae Ho Shim

Förderung

  • Korea University
  • National Research Foundation of Korea

Zitieren

APA

Shim, J. H., Lim, P., Woo, S., Han, J., & Kim, H. S. (2026). Discovery of a Quinazoline-Based Nav1.7 Inhibitor with MicroED-Confirmed Absolute Configuration and Oral Efficacy in Rodent Models of Neuropathic Pain. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02422

Vancouver

Shim JH, Lim P, Woo S, Han J, Kim HS. Discovery of a Quinazoline-Based Nav1.7 Inhibitor with MicroED-Confirmed Absolute Configuration and Oral Efficacy in Rodent Models of Neuropathic Pain. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c02422

BibTeX
@article{Shim2026,
  author = {Shim, Jae Ho and Lim, Pooreum and Woo, Sangwoo and Han, Jihye and Kim, Hyeon Soo},
  title = {Discovery of a Quinazoline-Based Nav1.7 Inhibitor with MicroED-Confirmed Absolute Configuration and Oral Efficacy in Rodent Models of Neuropathic Pain},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c02422}
}
Kostenlos starten →